Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa by Phillips, Andrew N et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
Phillips, Andrew N; Cambiano, Valentina; Revill, Paul; Nakagawa, Fumiyo; Lundgren, Jens
D.; Bansi-Matharu, Loveleen; Mabugu, Travor; Sculpher, Mark; Garnett, Geoff; Staprans,
Silvija; Becker, Stephen; Murungu, Joseph; Lewin, Sharon R; Deeks, Steven G; Hallett,
Timothy B
Published in:
The Journal of Infectious Diseases
DOI:
10.1093/infdis/jiw120
Publication date:
2016
Document license:
CC BY-NC
Citation for published version (APA):
Phillips, A. N., Cambiano, V., Revill, P., Nakagawa, F., Lundgren, J. D., Bansi-Matharu, L., ... Hallett, T. B.
(2016). Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. The Journal of
Infectious Diseases, 214, 73-79. https://doi.org/10.1093/infdis/jiw120
Download date: 03. Feb. 2020
The Journal of Infectious Diseases
M A J O R A R T I C L E
Identifying Key Drivers of the Impact of an HIV Cure
Intervention in Sub-Saharan Africa
Andrew N. Phillips,1 Valentina Cambiano,1 Paul Revill,3 Fumiyo Nakagawa,1 Jens D. Lundgren,4 Loveleen Bansi-Matharu,1 Travor Mabugu,5 Mark Sculpher,3
Geoff Garnett,7 Silvija Staprans,7 Stephen Becker,11 Joseph Murungu,6 Sharon R. Lewin,9,10 Steven G. Deeks,8 and Timothy B. Hallett 2
1Research Department of Infection & Population Health, UCL, 2Department of Infectious Disease Epidemiology, Imperial College London, and 3Centre for Health Economics, University of York, United
Kingdom; 4Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark; 5University of Zimbabwe, and 6Ministry of Health and Child Care, Harare, Zimbabwe; 7Bill & Melinda
Gates Foundation, Seattle, Washington; 8San Francisco General Hospital Medical Center, California; 9The Peter Doherty Institute for Infection and Immunity, University of Melbourne, and 10Department
of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; and 11Independent Consultant in HIV Global Health, Yountville, California
Background. It is unknown what properties would be required to make an intervention in low income countries that can erad-
icate or control human immunodeﬁciency virus (HIV) without antiretroviral therapy (ART) cost-effective.
Methods. We used a model of HIV and ART to investigate the effect of introducing an ART-free viral suppression intervention
in 2022 using Zimbabwe as an example country. We assumed that the intervention (cost: $500) would be accessible for 90% of the
population, be given to those receiving effective ART, have sufﬁcient efﬁcacy to allow ART interruption in 95%, with a rate of viral
rebound of 5% per year in the ﬁrst 3 months, and a 50% decline in rate with each successive year.
Results. An ART-free viral suppression intervention with these properties would result in >0.53 million disability-adjusted-life-
years averted over 2022–2042, with a reduction in HIV program costs of $300 million (8.7% saving). An intervention of this efﬁcacy
costing anything up to $1400 is likely to be cost-effective in this setting.
Conclusions. Interventions aimed at curing HIV infection have the potential to improve overall disease burden and to reduce
costs. Given the effectiveness and cost of ART, such interventions would have to be inexpensive and highly effective.
Keywords. HIV; cure; economic evaluation; model; antiretroviral therapy.
Research is ongoing into developing an intervention that would
allow human immunodeﬁciency virus (HIV)–infected individ-
uals to have prolonged, and perhaps permanent, viral suppres-
sion in the absence of therapy (“remission” or “cure”). We refer
to this as antiretroviral therapy (ART)–free viral suppression [1–
8]. The implications of this research for sub-Saharan Africa,
where most persons with HIV live, are as yet unclear, and any
such intervention requires consideration in the context of re-
source-constrained public health approaches to treatment and
prevention. Knowing what properties are likely to be required
of such an intervention for it to be cost-effective or cost saving
in low-income, high–HIV prevalence settings (ie, a “target
product proﬁle”) is important to enable focusing of research,
clinical development and delivery approaches.
In the current study, we sought to identify some basic product
and delivery attributes within a framework of a global policy
agenda. We addressed the following research questions. First,
what would be the predicted impact of an intervention to induce
sustained ART-free HIV suppression in low-income countries in
sub-Saharan Africa, in terms of death rates, HIV incidence, and
disability-adjusted life years (DALYs)? Second, under what con-
ditions, particularly those relating to efﬁcacy and cost, would
such an intervention represent a cost-effective approach, within
the context of continued expansion in access to ART?
METHODS
Model and Context
We assess these questions in the context of a generalized HIV
epidemic with ongoing ART rollout using a model that has been
informed by, and calibrated to, data from Zimbabwe [9–19].We
used the HIV Synthesis transmission model, an individual-
based stochastic model of heterosexual HIV transmission, pro-
gression, and treatment in adults that has been described
elsewhere ([20–23]; see Supplementary Material). Each simula-
tion run generates time-updated longitudinal “data” over time
for a population from 1989, such that the overall characteristics
in terms of age, sex, sexual risk behavior, and HIV status resem-
ble those of the entire adult population of Zimbabwe (HIV pos-
itive and negative). Transmission of HIV is modeled, with the
HIV status of each (condomless sex) partner being sampled,
along with viral load status of HIV-positive partners. For per-
sons who have become infected with HIV, the variables for
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which longitudinal data are simulated include viral load, CD4
cell count, presence of resistance mutations, diagnosis status,
linkage to care, maintenance in care and on treatment, and oc-
currence of AIDS and death.
Evaluation of the impact of an ART-free viral suppression
(AFVS) intervention depends on the predicted outcomes in the
absence of such an intervention and, in particular, the projected
long-term effects of ART. The ﬁrst-line regimen is assumed to be
a combination of efavirenz, lamivudine, and tenofovir, and the
second line regimen, ritonavir-boosted atazanavir, zidovudine,
and lamivudine. It is assumed that no third line will be available.
Table 1 presents the modeled 10- and 20-year outcomes after the
start of ART. These outputs reﬂect model assumptions regarding
adherence patterns, resistance acquisition, effect of adherence and
resistance on virologic outcome and CD4 cell count changes, and
the rate of interruption of ART and of ART toxicity, as detailed
elsewhere (Supplementary Material; [17, 24–29]).
We initially concentrate on a base-case analysis and then
consider a number of sensitivity analyses (Supplementary
Table 1). We assumed that rates of HIV testing and hence ART
coverage will continue to rise, although by lower amounts than
in the last 5 years and that the policy will be for ART initiation
in persons with CD4 cell counts <500 cells/µL and option B+
for pregnant women from 2015. Viral load monitoring of those
receiving ART is assumed to start from 2015 onward. We
also assume a modest increase in levels of condomless sex,
such that HIV incidence is projected to decline only modestly
(Supplementary Figure 2D). We assume continuation of trends
in male circumcision uptake and no introduction of preexpo-
sure prophylaxis.
AFVS Intervention
We envisaged an intervention that would induce AFVS, either
by activating and killing latently infected cells and thus deplet-
ing the reservoir to zero or close to zero or by enhancing long-
term immune control of a durable reservoir, with or without
reservoir reduction. We assume that the intervention is intro-
duced in 2022 and that 90% of persons in the country would
have access to the intervention should they fulﬁll the eligibility cri-
teria (50% in sensitivity analysis, which is perhaps more realistic if
the intervention requires intravenous administration). We assume
that the eligibility criteria for the intervention is an undetectable
viral load for ≥6 months and a CD4 cell count >500 cells/µL.
We consider that an AFVS intervention would most likely be
started in those in whom ART had initially been used to reduce
replicating virus.We assume that the AFVS intervention would be
administered for 6 months (while ART is continued).
We assume that 95% of those given the AFVS intervention
will be judged to have had a sufﬁcient response to be able to
stop ART. We then assume that failure—deﬁned as a rebound
in viremia—will occur initially at a rate of 0.05 per year in the
ﬁrst 3 months (eg, the probability of rebound is 0.05/4 in the
ﬁrst 3-month period), which declines thereafter by 50% per
year (so, for example, the probability of rebound in the second
3-month period is 0.05 × 0.50.25; this equates to approximately
8% of persons having viral rebound by 5 years after interruption
of ART; see Supplementary Figure 1). Viral load and CD4 T-cell
count dynamics during AFVS failure were assumed to be com-
parable to those of an ART interruption. During periods of
AFVS, we assume that the CD4 cell count will continue toTable 1. Model Outputs of Status in 2025 and 2035 for Persons Starting
ART in 2015a
Outcome
Persons Starting ART in 2015, %
10 y After Start
of ART (2025)
20 y After Start
of ART (2035)
On ART with VL <1000 copies/mL 53 31
On ART with VL >1000 copies/mL 6 3
Alive but off ART 9 5
Dead from HIV disease 20 40
Findings in those alive on ARTb
ART toxicity 37 34
Receiving second-line ART 24 37
NNRTI drug resistance 44 56
Resistance to NNRTI, NRTI, and PI
classes
1 2
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; NNRTI,
nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse-
transcriptase inhibitor; PI, protease inhibitor; VL, viral load.
a These outputs reflect model assumptions regarding multiple aspects, including
adherence patterns, resistance acquisition, effect of adherence and resistance
on virologic outcome and CD4 cell count changes, and the rates of interruption of
ART and ART toxicity. Full details of the modeling are given in the Supplementary
Material, along with details and comparison of outputs for adherence, virologic outcome,
NNRTI resistance, and ART discontinuation [20–29]; see references 20–23 for additional
details.
b Percentages in this grouping represent proportions of those alive on ART.
Figure 1. Overall program costs (in $m over 20 years; 2022–2042) according to
whether or not the antiretroviral therapy (ART)–free viral suppression (AFVS) inter-
vention is introduced (discounted at 3% per annum from 2015). Abbreviations: HIV,
human immunodeficiency virus; VL, viral load; WHO, World Health Organization.
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improve, as is the case with continued viral suppression during
ART. We also assume that CD4 cell count– and age-speciﬁc
morbidity and mortality rates will be no different from those
in persons receiving ART with viral suppression, including
that there remains some residual excess risk over and above
that in the uninfected population (1.3-fold excess risk assumed;
1.0- and 1.7-fold considered in sensitivity analysis) [30–32].We
also consider in sensitivity analysis that the excess risk is 1.3-
fold (and in a further sensitivity analysis that it is 1.7-fold) for
persons receiving ART with viral suppression and 1.0-fold for
those with AFVS.
We assume that individuals who have received the AFVS
intervention will be monitored with viral load tests every 3
months for the ﬁrst 5 years after ART interruption, and annu-
ally thereafter (as opposed to the annual monitoring throughout
for persons receiving ART). This is to try to ensure rapid iden-
tiﬁcation of viral rebound if it occurs. We further assume that
individuals with ongoing AFVS are susceptible to superinfec-
tion, which will lead to viral rebound, whereas those receiving
ART are assumed to not have risk of superinfection, owing to
the protective effects of ART.
Consequences of disengaging from care are different for per-
sons receiving ART and those with AFVS. For the former, ad-
herence to regular care/drug pick-up is essential for continued
viral suppression. In contrast, for those who have successfully
achieved AFVS, disengagement from care does not have nega-
tive consequences unless and until viral load rebound occurs.
Those receiving ART who experience viral rebound will be eli-
gible to be switched to the second-line regimen; the rate of
switch in such circumstances is 20% per 3 months once the
above failure criteria are met. Those receiving the AFVS inter-
vention are assumed to be given a maximum of 1 round.
Main Outcomes and Economic Analysis
The time perspective of the analysis was 20 years (2022–2042). The
main outcome is DALYs for individuals aged 15–65 years. The
DALY is a measure of overall disease burden. Persons incur a
fraction of a DALY for each period of time lived with a disabil-
ity, and a whole DALY for each year in which they have died
but would still be younger than 65 years had they lived. Only
HIV- or ART related disability is considered. The analysis
was from a health systems perspective. We consider DALYs
and costs in the whole population, not just those with HIV,
and effects of transmission are accounted for.
A one-off cost of the AFVS intervention of $500 ($200 and
$2000 in sensitivity analyses) is assumed (including cost of
viral load testing HIV in the time before, and the ﬁrst few
weeks after, ART interruption). The cost of clinic visits during
AFVS success is assumed to be $10 per 3 months ($5 in a sen-
sitivity analysis), compared with $20 for persons receiving ART
[33]; the cost is assumed to be lower because the person is not
receiving ART. The current annual per-person cost (including
supply chain) of ARVs is assumed to be $144 for the ﬁrst-line
and $312 for the second-line regimen [34].
The degree of disability experienced by a person, which is rel-
evant in calculation of DALYs, is measured on a scale of 0 (no
disability) to 1 (equivalent to death). We assume a toxicity of the
intervention that results in a disability weight of 0.25 for the 6-
month period of the intervention, but no increased mortality
risk. A weight of 0.25 is approximately that estimated for severe
diarrhea, acute low back pain, or acute gout, for example [35].
The disability weight due to living with diagnosed HIV is taken
as 0.1 [36]. This is removed in those with ongoing AFVS
success.
The cost-effectiveness threshold for a country represents the
opportunity costs of resources required to fund the interven-
tion, in terms of the health gains those resources could generate
if used for alternative purposes in the public health care system
[37]. As such, the threshold for a country is not readily appar-
ent, but $500 per DALY averted is likely to be at the upper end
based on the magnitude of beneﬁt were resources spent on
other programmatic priorities, such as eliminating coverage
gaps for ART, if these are large [38], reﬂecting competing
calls on HIV and non-HIV health care resources. This is just
more than half of gross domestic product per capita [39].
DALYS, life years, and costs were discounted from 2014 values
at 3% per annum. The AFVS intervention is considered cost
saving (or “dominant”) if it results in fewer DALYs and lower
cost, and cost-effective if it results in fewer DALYs and in-
creased costs but the cost per DALY averted is <$500.
RESULTS
The characteristics of the simulated population of Zimbabwe in
2014 and 2020 are shown in Table 2. Given assumptions that
rates of testing will increase at a moderate rate and that ART
initiation will be at CD4 cell count >500 cells/µL and with adop-
tion of option B+ for pregnant women, the proportion of per-
sons with an HIV diagnosis, and the number receiving ART is
projected to increase. As a result of these assumptions, approx-
imately 300 000 individuals aged 15–65 years are projected to be
both eligible for, and have access to, the AFVS intervention in
2022 (26% of the entire HIV-positive adult population in the
country at that time).
The proportion of persons who will receive the AFVS inter-
vention is expected to rise to 65% in 2042 (Supplementary Fig-
ure 2A). The number with ongoing AFVS (Supplementary
Figure 2B) is projected to approach a maximum of 550 000 by
the early 2030s. The incidence of AFVS failure (viral rebound)
is highest soon after the AFVS program is launched because
many will access the therapy when it ﬁrst becomes available,
and most failures occur early (Supplementary Figure 2C).
The incidence of HIV infection is projected to decline with or
without the AFVS intervention (owing to enduring effects of
earlier reductions in condomless sex in the mid 1990s and
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effects of viral suppression with ART), but it is projected to be
somewhat lower with the AFVS intervention (Supplementary
Figure 2D). Likewise, the prevalence of HIV infection (wherein
persons with ongoing AFVS success remain classiﬁed as HIV
positive) is projected to decline regardless of introduction of
the AFVS intervention, but slightly more rapidly with the inter-
vention (Supplementary Figure 2E). The number receiving ART
will decline to <700 000 by 2042 without the AFVS interven-
tion, and be <400 000 if the intervention is introduced (Supple-
mentary Figure 2F).
The overall proportion of persons with HIV with an unsup-
pressed viral load (>500 copies/mL) is projected to decline only
slowly from the level of 40% in 2022 without the AFVS inter-
vention but to decline to close to 25% with introduction of the
intervention (Supplementary Figure 2G). The death rate in
those with HIV infection is projected to be lower with the
AFVS intervention by about 0.5 per 100 person-years (8.4%
lower; Supplementary Figure 2H). DALYs (discounted) will be
slightly lower with the AFVS intervention (Supplementary Fig-
ure 2I). Costs are higher with the intervention in the initial few
years after introduction owing to the intervention itself but
lower thereafter, largely because fewer persons will be receiving
ART (Supplementary Figure 2J). Further outputs are shown in
Supplementary Figures 2K–BD.
With regard to projected costs, the main differences between
the scenarios with or without AFVS intervention are the cost of
ART, the cost of the AFVS intervention, the cost of clinic visits
(less expensive in those with suppression), and the cost of viral
load tests (done more frequently in persons with AFVS) (Fig-
ure 1). The AFVS intervention results in 539 738 DALYs
being averted (252 215 life years gained), which equates to an
average 2.6% reduction in death rate in the whole population
aged 15–65 years (Table 3). The AFVS intervention also results
in a cost reduction of $298 million (discounted), which repre-
sents an 8.7% reduction in the total budget over that period.
We also explored the effect of variations in assumptions on
the DALYs averted with the AFVS intervention (Supplementary
Figure 3). Assumptions about the degree to which ART is
Table 2. Characteristics of the Simulated Population of Zimbabwe in 2014 and 2020
Output 2014 2020 Observed Data
Population aged 15–65 y 7 971 000 8 946 000 8 000 000a
Persons tested for HIV (per 3 mo), No. 687 000 882 000 2 274 328 aged 15–49 y tested in 2013b
Proportion of men circumcised (aged 15–65 y) 0.27 0.46 0.26 in men aged 15–29 in 2014c
Incidence of HIV (per 100 person-years) in persons aged 15–65 y 0.99 0.61 0.98 in 2013b
Prevalence of HIV in persons aged 15–49 y 0.14 0.11 0.15 in 2011 DHSd
Persons living with HIV, No. 1 167 000 1 124 000 . . .
Of persons with HIV, proportion diagnosed 0.84 0.91 . . .
Persons on ART (aged 15–65 y), No. 678 000 801 000 Approximately 700 000 on 1 January 2015e
Of persons with HIV diagnosis, proportion ever starting ART 0.75 0.87 . . .
Of persons with HIV diagnosis, proportion on ART 0.58 0.78 . . .
Death rate (per 100 person-years) in whole adult population aged 15–65 y 1.81 1.57 1.15 in persons aged 15–49 yd
Death rate (per 100 person-years) in persons with HIV aged 15–65 y 5.45 4.54 . . .
Death rate (per 100 person-years) in persons on ART aged 15–65 y 4.13 3.20 . . .
Of persons on ART, proportion with VL <500 copies/mL 0.81 0.84 0.78f
Of persons who ever started ART, proportion who started 2nd-line regimen 0.05 0.19 <0.02e
Of persons with HIV, proportion with VL >500 copies/mL 0.52 0.39 . . .
Of persons who ever started ART, proportion in whom 1st-line regimen has failed 0.13 0.24 . . .
Abbreviations: ART, antiretroviral therapy; DHS, Demograhic and Health Survey; HIV, human immunodeficiency virus; VL, viral load.
a Data from the Central Intelligence Agency [15].
b Data from UNAIDS [16].
c Data from Population Services International, Zimbabwe (personal communication).
d Data from the Zimbabwe National Statistics Agency (ZIMSTAT) and ICF International [18].
e Unpublished data (J. M.).
f Baseline results from the Sisters ART Programme for Prevention of HIV—an Integrated Response (SAPPH-IRe) trial [19]. Also, estimate of 0.90 reported in ref [17].
Table 3. Discounted DALYs and Costs Over 20 Years (2022–2042) With or
Without ART-Free Viral Suppression Intervention (Base Case)
DALYs and Costs
AFVS Intervention
Yes No
DALYs 46 610 496 47 150 234
DALYs averteda 539 738 . . .
Costs, $ (in millions)b 3 139 3 437
Increment in costs, $ (in millions)a -$298 . . .
Abbreviations: AFVS, ART-free viral suppression; ART, antiretroviral therapy; DALYs,
disability-adjusted life years.
a Compared with no AFVS intervention.
b There is an 8.7% reduction in costs with AFVS intervention.
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expected to be durably successful affect the magnitude of beneﬁt
of the AFVS intervention. In particular, when we assume a
higher rate of interruption of ART (such that only 63% of
ART experienced persons have a viral load <500 copies/mL,
compared with 73% in the base case), the intervention beneﬁt
is greater. The beneﬁt of the AFVS intervention is also greater if
we assume that the rate ratio compared with the HIV-negative
population for the non-AIDS mortality rate in persons with
AFVS success is 1.0, but is higher (at 1.3- or 1.7-fold) for
those with viral suppression during ART. If the disability weight
from ART toxicity is assumed to be 0.15 rather than 0.05, then
the impact of the AFVS intervention is again greater.
Figure 2 presents the cost-effectiveness of the AFVS interven-
tion according to variation in combinations of key uncertain pa-
rameters of AFVS efﬁcacy and access and cost parameters. The
most strongly inﬂuential of these factors for cost-effectiveness is
the cost of the AFVS intervention, with the efﬁcacy of the inter-
vention (degree of reduction in the viral rebound rate from the
initial rate of 0.05 per year) also inﬂuential. In the context of the
base case, the threshold cost of the AFVS intervention to be
cost-effective is $1400, and the threshold to be cost saving is
$975. If the AFVS intervention efﬁcacy is lower, such that the
percentage reduction in viral rebound rate per year is instead
20%, then the threshold cost of the AFVS intervention is
$1000 to be cost-effective and $700 to be cost saving.
DISCUSSION
In this modeling and economic evaluation we have assessed what
properties an intervention aimed at HIV cure should have for it
to represent a cost-effective option in low-resource settings. The
Figure 2. Results of multiway sensitivity analysis showing the effects of (1) efficacy and access of the antiretroviral therapy (ART)–free viral suppression (AFVS) intervention
and (2) unit costs, on cost-effectiveness and level of cost saving. In the context of the base case, highlighted—90% of persons with access, 50% reduction in viral rebound rate
per year, $22 for cost of viral load (VL), $10 for cost of visits during AFVS—the threshold cost of the AFVS intervention to be cost-effective was $1400, and the threshold to be
cost saving was $975. Abbreviation: DALYs, disability-adjusted life years.
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key determinants of the cost-effectiveness/impact of an AFVS in-
tervention are the efﬁcacy of the intervention (as deﬁned by the
rate of rebound over time) and the cost of the intervention. With
the efﬁcacy assumed in our base case, the AFVS intervention
would need to cost <$1400 to be cost-effective.
The predicted beneﬁts of an AFVS intervention depend on
our predicted outcomes of ART. It is difﬁcult to be certain
about long-term outcomes of ART when potent regimens
have been in use for <20 years, and for little more than 12
years in southern Africa. However, data on levels of viral sup-
pression from sub-Saharan Africa indicate that therapy is highly
effective [29, 40–43]. Long-term rates of virologic rebound in
high-income settings have shown low and decreasing rates of
viral rebound over time [28, 44]. Our sensitivity analyses suggest
that if our model proves to be overly optimistic regarding ART
efﬁcacy—which is plausible given experiences in high-income
countries—then more expensive AFVS interventions would be-
come cost-effective and cost saving.
The costs associated with adopting the AFVS intervention are
highest soon after introduction owing to the cost of the inter-
vention itself and the increased intensity of viral load monitor-
ing required in the initial period after the interruption. Without
such frequent monitoring—3 monthly for 5 years—a signiﬁcant
proportion of persons could experience a sustained period of
high-level viremia (higher than in those with viral breakthrough
during ART). Over the longer term within our 20-year time ho-
rizon (to 2042) the AFVS intervention is associated with lower
costs than continued ART.
The intention of this evaluation is to provide a source of guid-
ance as research into potential AFVS interventions moves for-
ward. The potential impact of an HIV vaccine has been
evaluated in such a way previously [23, 45]. In addition, modeling
and cost-effectiveness analyses have been used to identify the
attributes of different types of cure approaches required to be
cost-effective [46]. Speciﬁc cure strategies that were considered
included gene therapy, chemotherapy, and stem cell transplanta-
tion. There are many similarities in the approach used with our
own, with the use of individual-based simulation models that
consider possible relapse rates and the consequences. The main
differences concern our focus on sub-Saharan Africa rather than
high-income settings, with substantial implications for the cost of
cure regimens that might be cost-effective, and our inclusion via a
dynamic transmission model of effects on HIV incidence.
In building our model of the AFVS intervention, we have not
explicitly distinguished between an intervention that results in
HIV eradication and one that results in sustained immune con-
trol of HIV. In the latter situation, the advantages might be that
viral rebound, if it occurs, would be less dramatic, and that there
may be protection from superinfection. A potential disadvan-
tage is that, owing to the presence of low levels of virus, immune
activation may persist, with less restoration of health. A poten-
tial additional beneﬁt of an AFVS intervention that we did not
include is that the availability of a cure may give an added im-
petus to ART programs and lead to higher levels of HIV testing
and greater engagement with, and adherence to, ART with the
prospect of access to the intervention.
One limitation of our work is that we naturally have had to
make a number of assumptions. The success of prevention efforts
and future HIV incidence are uncertain, although the impact of
the AFVS intervention is not highly sensitive to these factors. The
greatest uncertainties concerning this impact relate to the prop-
erties of the intervention and, to a lesser extent, the future effects
of ART. In addition, we considered a time scale of 20 years, and
the impact of the intervention would be expected to become
greater with time, after a large initial investment. In addition,
we assumed that third-line regimens are not available when in
fact small numbers in Zimbabwe are using third-line regimens.
We also assumed that preexposure prophylaxis would not be
available, when it is likely to be used in future to some extent.
In conclusion, a new AFVS intervention has the potential to
avert DALYs and result in substantial cost savings in HIV care.
However, the intervention will need to meet a stringent set of
speciﬁcations for this to be the case. The cure ﬁeld can use mod-
els such as our to better deﬁne its product development and de-
livery system imperatives.
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Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
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questions or comments should be addressed to the author.
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